Pure Global
NCT04428346

A Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs

A Pilot Two-arm, Individual-level, Randomised Controlled Trial to Assess the Effect of an Intervention Integrating Contingency Management (Financial Incentives) to Enhance Hepatitis C Treatment Uptake Following Dried Blood Spot Hepatitis C RNA Testing Among People With Recent Injecting Drug Use Attending Needle and Syringe Programs
Kirby Institute·ClinicalTrials.gov·behavioralNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Hepatitis C, Chronic
Drug/Device/Intervention
Incentive payment
Study type
Interventional
Intervention type
behavioral
Sponsor & location
Primary sponsor
Kirby Institute
Timeline & enrollment
Phase
N/A
Start date
Mar 01, 2022
End date
Dec 01, 2022
Enrollment
400 participants
Primary outcome

The proportion of participants who initiate Hepatitis C Virus treatment within 12 weeks of testing

Summary

A pilot two-arm, individual-level, randomised controlled trial to assess the effect of an
 intervention integrating contingency management (financial incentives) to enhance hepatitis C
 treatment uptake following dried blood spot hepatitis C RNA testing among people with recent
 injecting drug use attending needle and syringe programs: the AMPLIFY study

ICD-10 classifications
Chronic viral hepatitis CAcute hepatitis CChronic hepatitis, unspecifiedChronic viral hepatitisChronic viral hepatitis, unspecified
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT04428346
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT04428346 through Pure Global AI's free database. This phase not specified trial is sponsored by Kirby Institute and is currently Not yet recruiting. The study focuses on Hepatitis C, Chronic. Target enrollment is 400 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.